In a study that compared subjects with PWS receiving GH therapy (starting age 4–20 months) with those who did not, it was reported that the treated group had a lower body fat, increased muscle mass, better lipid profile and better motor function [24], thus suggesting that early treatment might explain the significant differences observed. This evidence concerns the gene GH1 and Prader-Willi syndrome.